# Bioequivalence Study of Fingolimod From Sphingomod 0.5 mg Hard Gelatin Capsules (Hikma Pharma, Egypt) Versus Gilenya 0.5 mg Hard Capsules (Novartis Pharma AG, Basle, Switzerland).

> **NCT04657744** · PHASE1 · COMPLETED · sponsor: **Genuine Research Center, Egypt** · enrollment: 34 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Sphingomod
- **DRUG:** Gilenya

## Key facts

- **NCT ID:** NCT04657744
- **Lead sponsor:** Genuine Research Center, Egypt
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-10
- **Primary completion:** 2020-09-28
- **Final completion:** 2020-10-20
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2020-12-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04657744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04657744, "Bioequivalence Study of Fingolimod From Sphingomod 0.5 mg Hard Gelatin Capsules (Hikma Pharma, Egypt) Versus Gilenya 0.5 mg Hard Capsules (Novartis Pharma AG, Basle, Switzerland).". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04657744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*